Case report: Immunotherapy plus chemotherapy and stereotactic ablative radiotherapy (ICSABR): a novel treatment combination for Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma
Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma (EBVa LEL-ICC) is a rare tumor, characterized by a rich tumor immune microenvironment (TIME). While this tumor is reportedly sensitive to immunotherapy, its response has been inconsistent. This decreased sensitivity...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1147449/full |
| _version_ | 1797751341068582912 |
|---|---|
| author | Ruizhen Li Ke Cheng Xiaofen Li Chen Chang Wanrui Lv Li Xiaoying Pei Zhang Heqi Yang Dan Cao |
| author_facet | Ruizhen Li Ke Cheng Xiaofen Li Chen Chang Wanrui Lv Li Xiaoying Pei Zhang Heqi Yang Dan Cao |
| author_sort | Ruizhen Li |
| collection | DOAJ |
| description | Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma (EBVa LEL-ICC) is a rare tumor, characterized by a rich tumor immune microenvironment (TIME). While this tumor is reportedly sensitive to immunotherapy, its response has been inconsistent. This decreased sensitivity was associated with reduced TIME abundance. We report the case of a 53-year-old woman with EBVa LEL-ICC having reduced TIME abundance. The patient presented with a liver lesion, which was detected using ultrasound. Initially, the tumor was sensitive to immunotherapy and chemotherapy (IC), but resistance developed after a short interval. Subsequently, stereotactic ablative radiotherapy (SABR) was added to the patient’s treatment, which now consisted of ICSABR. Successful tumor shrinkage was achieved with the combination therapy regimen. Thus, surgery and ICSABR are effective adjuncts to the first-line IC therapy in improving the survival rate of patients with EBVa LEL-ICC. The results of this study support multidisciplinary treatment as a viable treatment strategy for EBVa LEL-ICC. |
| first_indexed | 2024-03-12T16:46:02Z |
| format | Article |
| id | doaj.art-e207fa4750c3449bb5046e7b291a8c06 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-12T16:46:02Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-e207fa4750c3449bb5046e7b291a8c062023-08-08T12:39:30ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-08-011410.3389/fphar.2023.11474491147449Case report: Immunotherapy plus chemotherapy and stereotactic ablative radiotherapy (ICSABR): a novel treatment combination for Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinomaRuizhen Li0Ke Cheng1Xiaofen Li2Chen Chang3Wanrui Lv4Li Xiaoying5Pei Zhang6Heqi Yang7Dan Cao8West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan, ChinaDivision of Medical Oncology, State Key Laboratory of Biotherapy, Abdominal Oncology Ward, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaEpstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma (EBVa LEL-ICC) is a rare tumor, characterized by a rich tumor immune microenvironment (TIME). While this tumor is reportedly sensitive to immunotherapy, its response has been inconsistent. This decreased sensitivity was associated with reduced TIME abundance. We report the case of a 53-year-old woman with EBVa LEL-ICC having reduced TIME abundance. The patient presented with a liver lesion, which was detected using ultrasound. Initially, the tumor was sensitive to immunotherapy and chemotherapy (IC), but resistance developed after a short interval. Subsequently, stereotactic ablative radiotherapy (SABR) was added to the patient’s treatment, which now consisted of ICSABR. Successful tumor shrinkage was achieved with the combination therapy regimen. Thus, surgery and ICSABR are effective adjuncts to the first-line IC therapy in improving the survival rate of patients with EBVa LEL-ICC. The results of this study support multidisciplinary treatment as a viable treatment strategy for EBVa LEL-ICC.https://www.frontiersin.org/articles/10.3389/fphar.2023.1147449/fullEpstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinomatumor immune microenvironmentimmunotherapystereotactic ablative radiotherapylong survival |
| spellingShingle | Ruizhen Li Ke Cheng Xiaofen Li Chen Chang Wanrui Lv Li Xiaoying Pei Zhang Heqi Yang Dan Cao Case report: Immunotherapy plus chemotherapy and stereotactic ablative radiotherapy (ICSABR): a novel treatment combination for Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma Frontiers in Pharmacology Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma tumor immune microenvironment immunotherapy stereotactic ablative radiotherapy long survival |
| title | Case report: Immunotherapy plus chemotherapy and stereotactic ablative radiotherapy (ICSABR): a novel treatment combination for Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma |
| title_full | Case report: Immunotherapy plus chemotherapy and stereotactic ablative radiotherapy (ICSABR): a novel treatment combination for Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma |
| title_fullStr | Case report: Immunotherapy plus chemotherapy and stereotactic ablative radiotherapy (ICSABR): a novel treatment combination for Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma |
| title_full_unstemmed | Case report: Immunotherapy plus chemotherapy and stereotactic ablative radiotherapy (ICSABR): a novel treatment combination for Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma |
| title_short | Case report: Immunotherapy plus chemotherapy and stereotactic ablative radiotherapy (ICSABR): a novel treatment combination for Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma |
| title_sort | case report immunotherapy plus chemotherapy and stereotactic ablative radiotherapy icsabr a novel treatment combination for epstein barr virus associated lymphoepithelioma like intrahepatic cholangiocarcinoma |
| topic | Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma tumor immune microenvironment immunotherapy stereotactic ablative radiotherapy long survival |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1147449/full |
| work_keys_str_mv | AT ruizhenli casereportimmunotherapypluschemotherapyandstereotacticablativeradiotherapyicsabranoveltreatmentcombinationforepsteinbarrvirusassociatedlymphoepitheliomalikeintrahepaticcholangiocarcinoma AT kecheng casereportimmunotherapypluschemotherapyandstereotacticablativeradiotherapyicsabranoveltreatmentcombinationforepsteinbarrvirusassociatedlymphoepitheliomalikeintrahepaticcholangiocarcinoma AT xiaofenli casereportimmunotherapypluschemotherapyandstereotacticablativeradiotherapyicsabranoveltreatmentcombinationforepsteinbarrvirusassociatedlymphoepitheliomalikeintrahepaticcholangiocarcinoma AT chenchang casereportimmunotherapypluschemotherapyandstereotacticablativeradiotherapyicsabranoveltreatmentcombinationforepsteinbarrvirusassociatedlymphoepitheliomalikeintrahepaticcholangiocarcinoma AT wanruilv casereportimmunotherapypluschemotherapyandstereotacticablativeradiotherapyicsabranoveltreatmentcombinationforepsteinbarrvirusassociatedlymphoepitheliomalikeintrahepaticcholangiocarcinoma AT lixiaoying casereportimmunotherapypluschemotherapyandstereotacticablativeradiotherapyicsabranoveltreatmentcombinationforepsteinbarrvirusassociatedlymphoepitheliomalikeintrahepaticcholangiocarcinoma AT peizhang casereportimmunotherapypluschemotherapyandstereotacticablativeradiotherapyicsabranoveltreatmentcombinationforepsteinbarrvirusassociatedlymphoepitheliomalikeintrahepaticcholangiocarcinoma AT heqiyang casereportimmunotherapypluschemotherapyandstereotacticablativeradiotherapyicsabranoveltreatmentcombinationforepsteinbarrvirusassociatedlymphoepitheliomalikeintrahepaticcholangiocarcinoma AT dancao casereportimmunotherapypluschemotherapyandstereotacticablativeradiotherapyicsabranoveltreatmentcombinationforepsteinbarrvirusassociatedlymphoepitheliomalikeintrahepaticcholangiocarcinoma |